What Orogen Therapeutics does

Orogen Therapeutics is a privately held, Woburn, Massachusetts-based drug discovery company founded in 2023 that is developing oral small molecule therapies for immuno-inflammatory (INI) disorders using its proprietary, AI-enabled DNA-encoded library (DEL) screening platform called FocusDEL™. The platform combines 180+ target-specific DELs spanning 54,000+ building blocks and 22 billion screenable compounds with virtual screening, computational chemistry, and AI/ML modules that drive binding affinity prediction, multi-parameter optimization, and DMTA cycles. The company's internal pipeline includes 12+ small molecule programs against validated cytokine targets such as IL-17, TNFα, and TL1A, with multiple candidates in lead optimization advancing toward IND-enabling studies; the company also references additional undisclosed targets and has demonstrated the platform's applicability to challenging protein-protein interactions.

The business is currently pre-revenue with no disclosed pricing, licensing, or collaboration economics in the source material; the implied model — consistent with a platform biotech at this stage — is preclinical R&D collaborations, option-to-license arrangements, and milestone-based deals with pharmaceutical partners, though no executed deals or named customers are confirmed. Primary customer segment is pharmaceutical companies seeking novel small-molecule starting points and differentiated targets in immuno-inflammatory disease. Orogen's GTM motion is enterprise-focused business development into pharma R&D and licensing functions. Capital structure is anchored by a $12.25M seed round (June 2023) from Anterra Capital and Novalis Capital Partners, and the company is led by CEO Mark Pykett (appointed April 2025), CSO Artem Evdokimov, and a board that includes Mikael Dolsten (former Pfizer CSO), Dieter Weinand (former Bayer Pharma CEO), Phil Austin (Anterra), and Marijn Dekkers (Novalis). Operational scale is 11–50 employees as of the most recent disclosure.

Name

Orogen Therapeutics

Legal name

Orogen Therapeutics, Inc.

Website

https://orogentx.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

11–50 employees

Short description

Orogen Therapeutics is a private, Woburn, MA-based drug discovery company developing oral small molecule therapies for immuno-inflammatory disorders using its proprietary AI-enabled FocusDEL™ DNA-encoded library platform. It targets validated cytokine pathways including IL-17, TNFα, and TL1A, serving pharmaceutical partners via R&D collaboration and licensing.

Ownership category

akta.pro rank

Product category

Drug Discovery Services

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Analytical Laboratory Instrument Manufacturing (334516)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries) (HLAAAIAL)

akta.pro secondary industries

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)

Keywords

• DNA-encoded libraries
• Small molecule drug discovery
• AI drug discovery
• Immuno-inflammatory therapeutics
• Cytokine inhibitors

Headquarters

HQ city

Woburn

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Pre-revenue drug discovery platform: No verifiable revenue stream information was available in the provided source material. As a drug discovery platform company, plausible revenue streams would include R&D collaborations, licensing, and milestone payments, but these are not confirmed by any supplied source.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Orogen Therapeutics operates an AI-enabled DNA-encoded library (DEL) drug discovery platform centered on its proprietary, patent-pending FocusDEL™ technology. The platform integrates 180+ DELs covering more than 22 billion screenable compounds with AI/ML, computational chemistry, virtual screening, and bioinformatics to identify novel small-molecule hits against validated cytokine targets (IL-17, TNFα, TL1A and additional undisclosed targets) for immuno-inflammatory disorders. Orogen monetizes its discovery engine through R&D collaborations and out-licensing of pipeline assets to pharmaceutical partners.

Product overview

Orogen Therapeutics offers a single, unified DNA-encoded library (DEL) drug discovery platform built on its proprietary FocusDEL™ technology. The FocusDEL™ engine is the core product and is wrapped by an integrated stack of platform capabilities — AI/ML and computational chemistry, virtual screening, and bioinformatics — that together drive the company's internal pipeline of small molecule programs (IL-17, TNFα, TL1A, and additional undisclosed targets). In other words, FocusDEL™ is the discovery engine; AI/ML, computational chemistry, and virtual screening are the supporting modules layered on top of it; and the IL-17, TNFα, TL1A, and other named programs are the pipeline assets that the platform produces. No separate commercial products, modules, or sub-brands are offered externally.

Differentiator

Problem solved

Functional benefit

Products and services

• FocusDEL™ Platform
• Immuno-inflammatory Pipeline Programs

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Partnerships

Two partnerships are on record, tiered core.

• ChemspacecoreStrategic or Co-development Partner · 16 July 2025Referenced in the supplied thinking block as a strategic collaborator for REAL-driven DNA-encoded libraries. No source passage with a verifiable WX-prefixed source ID was provided to confirm the partnership details.
• EnaminecoreStrategic or Co-development Partner · 16 July 2025Referenced in the supplied thinking block as a strategic collaborator for REAL-driven DNA-encoded libraries. No source passage with a verifiable WX-prefixed source ID was provided to confirm the partnership details.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Schrödinger: Schrödinger is a computational chemistry and AI-driven drug discovery platform with both internal pipeline and software offerings. It is comparable to Orogen in combining AI/ML with small-molecule discovery, but at a much larger and more established scale.
• Pharmaron: Pharmaron is a global CRO providing integrated drug discovery and development services, including DEL-related chemistry and in-vitro biology. It is comparable to Orogen as a discovery services provider but at significantly greater scale and scope.
• WuXi AppTec: WuXi AppTec operates a broad CRO/CDMO platform with DEL capability (WuXi DEL) and discovery services. It is a larger, diversified competitor and partner in the DEL and small-molecule CRO space where Orogen operates.
• Nuevolution (Amgen): Nuevolution was a pioneer in DEL-based drug discovery before being acquired by Amgen in 2019. It represents the strategic exit path and incumbent competitive benchmark that Orogen is building toward.

Emerging players

• Insilico Medicine: Insilico Medicine uses generative AI and target identification to advance small-molecule programs into the clinic. It is comparable to Orogen as an AI-enabled small-molecule discovery company building an internal pipeline.
• Recursion Pharmaceuticals: Recursion is an AI-driven drug discovery company combining high-throughput biology with machine learning. It is thematically comparable to Orogen as an emerging AI + experimental platform pursuing internal pipelines and pharma partnerships.

Direct peers

• Vipergen: Vipergen offers DEL and DNA-templated chemistry-based screening services for small-molecule discovery. It is comparable to Orogen as a specialized DEL platform serving pharma partners.
• Philochem: Philochem is a DEL-focused discovery company with proprietary encoded library chemistry. It directly parallels Orogen's target-specific FocusDEL™ approach to small-molecule hit generation.
• HitGen: HitGen is a publicly listed DEL pioneer with one of the largest DEL collections in the industry and an integrated drug discovery platform. It competes head-to-head with Orogen for DEL-driven hit identification and target-based discovery partnerships.
• X-Chem: X-Chem is a DNA-encoded library (DEL) discovery company that screens large, diverse libraries against customer-supplied targets. It is the most direct competitor to Orogen's FocusDEL™ platform in the DEL-based small-molecule discovery space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Orogen Therapeutics